International Journal of Drug Delivery Technology
Volume 14, Issue 1

Unraveling the Therapeutic Prospects of Solid Lipid Nanoparticles for the Treatment of Parasitic Diseases

Harman Singh, Manveer Singh, Navdeep Singh, Himanshu Jain, Honey Goel*, Viney Chawla

University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Faridkot, Punjab, India.

Received: 18th December, 2023; Revised: 21st January, 2024; Accepted: 06th March, 2024; Available Online: 25th March, 2024

ABSTRACT

Parasites induce a spectrum of illnesses, ranging from mild to severe, often causing significant global outbreaks. Existing antiparasitic drugs exhibit toxicity and notable side effects. Nanocarriers offer a promising solution by mitigating these issues through reduced side effects, enhanced target delivery, and additionally regulated prolonged active ingredient release. Solid lipid nanoparticles (SLNs), a subset of lipid nanoparticles (LNPs), have gained prominence for their favorable attributes. SLNs present themselves as a feasible option among colloidal carriers, offering an optimal release rate, stability, and precise target delivery. Their potential to deliver natural antiparasitic products is particularly noteworthy. Recent advancements in utilizing nanoparticles to enhance SLN stability and loading capacity are also explored in this review. The narrative encompasses SLN development, preparation methods, characterization, and the incorporation of drugs for combating parasitic diseases, offering insights into the evolving landscape of antiprotozoal SLN-saturated medications.

Keywords: Nano-sized carriers, SLN formulations, Drug administration, Protozoans, Helminthic parasites. International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.1.64

How to cite this article: Singh H, Singh M, Singh N, Jain H, Goel H, Chawla V. Unraveling the Therapeutic Prospects of Solid Lipid Nanoparticles for the Treatment of Parasitic Diseases. International Journal of Drug Delivery Technology. 2024;14(1):447-462.

REFERENCES

  1. Thiruvengadam M, Rajakumar G, Chung IM. Nanotechnology: current uses and future applications in the food 3 Biotechnology. 2018;8(1):74. Available from: https://doi. org/10.1007/s13205-018-1104-7
  2. Nasrollahzadeh M, Sajadi SM, Sajjadi M, Issaabadi Chapter 4-Applications of nanotechnology in daily life. In: Nasrollahzadeh M, Sajadi SM, Sajjadi M, Issaabadi Z, Atarod M, editors. Interf Sci Technol, vol. 28. Amsterdam: Elsevier; 2019. p. 113–43. Available from: https://doi.org/10.1016/B978-0-12-813586-0.00004-3.
  3. Neme K, Nafady A, Uddin S, Tola YB. Application of nanotechnology in agriculture, postharvest loss reduction and food processing: food security implication and challenges. Heliyon. 2021;7(12): e08539. Available from: https://doi. org/10.1016/j.heliyon.2021.e08539.
  4. Jeevanandam J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials: history, sources, toxicity and Beilstein J Nanotechnol. 2018; 9:1050–74. Available from: https://doi.org/10.3762/bjnano.9.98.
  5. Zdrojewicz Z, Waracki M, Bugaj B, Pypno D, Cabała K. Medical applications of nanotechnology. Postep Hig Med Doswiad (Online). 2015; 69:1196–204. Available from: https:// org/10.5604/17322693.1177169.
  6. Havel H, Finch G, Strode P, Wolfgang M, Zale S, Bobe I, Youssoufan H, Peterson M, Liu Nanomedicines: from bench to bedside and beyond. AAPS J. 2016;18(6):1373–8. Available from: https://doi.org/10.1208/s12248-016-9961-7.
  7. Bonifácio BV, Silva PB, Ramos MA, Negri KM, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: a Int J Nanomed. 2014;9:1–15. Available from: https://doi.org/10.2147/ijn.s52634.
  8. Nemati S, Shalileh F, Mirjalali H, Omidfar Toward waterborne protozoa detection using sensing technologies. Front Microbiol. 2023;14:1118164. Available from: https://doi.org/10.3389/ fmicb.2023.1118164.
  9. Mirza AZ, Siddiqui Nanomedicine and drug delivery: a mini review. Int Nano Lett. 2014;4(1):1–7.
  10. Watkins R, Wu L, Zhang C, Davis RM, Xu B. Natural product- based nanomedicine: recent advances and Int J Nanomed. 2015; 10:6055.
  11. Barratt Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci. 2003;60(1):21–37. Available from: https://doi.org/10.1007/s000180300002.
  12. Ventola CL. The nanomedicine revolution: part 1: emerging concepts. Peer Rev J Formular Manag. 2012;37(9):512–25.
  13. Havel Where are the nanodrugs? an industry perspective on development of drug products containing nanomaterials. AAPS2016;18(6):1351–3. Available from: https://doi.org/10.1208/ s12248-016-9970-6.
  14. Caster JM, Patel AN, Zhang T, Wang A. Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017. Available from: https://doi.org/10.1002/ 1416.
  15. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical t r ials to Pharmaceut Res. 2016;33(10):2373–87. Available from: https://doi.org/10.1007/ s11095-016-1958-5.
  16. Stanberry LR, Simon JK, Johnson C, Robinson PL, Morry J, Flack MR, Gracon S, Myc A, Hamouda T, Baker JR Jr. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine. 2012;30(2):307–16. Available from: https:// org/10.1016/j.vaccine.2011.10.094.
  17. Ventola CL. Progress in nanomedicine: approved and investigational Peer-Rev J Formul Manag. 2017;42(12):742–55.
  18. Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect 2013;3:13. Available from: https://doi.org/10.3389/fcimb.2013.00013.
  19. Weers JG. Colloidal particles in drug delivery. Curr Opin Colloid Interf 1998;3(5):540–4. Available from: https://doi. org/10.1016/S1359-0294(98)80030-7.
  20. Nagati V, Tenugu S, Pasupulati AK. Chapter 4-Stability of therapeutic nano-drugs during storage and transportation as well as after ingestion in the human body. In: Das Talukdar A, Dey Sarker S, Patra JK, editors. Advances in nanotechnology- based drug delivery systems. Amsterdam: Elsevier; 2022. p. 83–102. Available from: https://doi.org/10.1016/B978-0-323- 88450-1.00020-X.
  21. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MdP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin H-S. Nano based drug delivery systems: recent developments and future J Nanobiotechnol. 2018;16(1):71. Available from: https://doi. org/10.1186/s12951-018-0392-8.
  22. Baek J-S, Cho C-W. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Eur J Pharmaceut Biopharmaceut. 2017; 117:132–40. Available from: https://doi.org/10.1016/j.ejpb.2017.04.013.
  23. Global report on antimalarial efficacy and drug resistance:2000–2010. WHO; 2010. p. 2023.
  24. Murray CJL, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012;379(9814):413–31.
  25. Taghipour A, Javanmard E, Rahimi HM, Abdoli A, Matin S, Haghbin M, Olfatifar M, Mirjalali H, Zali Prevalence of intestinal parasitic infections in patients with diabetes: a systematic review and meta-analysis. Int Health. 2023. Available from: https://doi.org/10.1093/inthealth/ihad0
  26. Liu LX, Weller PF. Antiparasitic drugs. New Engl J Med. 1996;334(18):1178–84. Available from: https://doi.org/10.1056/
  27. Katz Adverse metabolic effects of antiparasitic drugs. Rev Infect Dis. 1982;4(4):768–70. Available from: https://doi. org/10.1093/4.4.768.
  28. Farahmandian I, Arfaa F, Jalali H, Reza Comparative studies on the evaluation of the effect of new anthelminthics on various intestinal helminthiasis in Iran. Effects of anthelminthics on intestinal helminthiasis. Chemotherapy. 1977;23(2):98–105. Available from: https://doi.org/10.1159/000221977.
  29. Khosravi M, Mohammad Rahimi H, Doroud D, Mirsamadi ES, Mirjalali H, Zali MR. In vitro evaluation of mannosylated paromomycin-loaded solid lipid nanoparticles on acute toxoplasmosis. Front Cell Infect Microbiol. 2020; 10:33.
  30. Nemati S, Mohammad Rahimi H, Hesari Z, Sharifdini M, Jalilzadeh Aghdam N, Mirjalali H, Zali MR. Formulation of Neem oil-loaded solid lipid nanoparticles and evaluation of its anti-Toxoplasma activity. BMC Complement Med Therap. 2022;22(1):1–11.
  31. Pires VC, Magalhães CP, Ferrante M, de Souza RJ, Nguewa P, Severino P, Barral A, Veras PST, Formiga Solid lipid nanoparticles as a novel formulation approach for tanespimycin (17-AAG) against Leishmania infections: preparation, characterization and macrophage uptake. Act Trop. 2020; 211:105595.
  32. Parvez S, Yadagiri G, Gedda MR, Singh A, Singh OP, Verma A, Sundar S, Mudavath SL. Modified solid lipid nanoparticles encapsulated with amphotericin B and paromomycin: an effective oral combination against experimental murine visceral Leishmania Sci Rep. 2020;10(1):1–14.
  33. Singh A, Yadagiri G, Parvez S, Singh OP, Verma A, Sundar S, Mudavath SL. Formulation, characterization and in vitro anti- Leishmanial evaluation of amphotericin B loaded solid lipid nanoparticles coated with vitamin B12-stearic acid conjugate. Mater Sci Eng C. 2020; 117:111279.
  34. Kharaji MH, Doroud D, Taheri T, Rafati Drug targeting to macrophages with solid lipid nanoparticles harboring paromomycin: an in vitro evaluation against L. major and L. tropica. AAPS Pharm Sci Tech. 2016;17(5):1110–9.
  35. Heidari-Kharaji M, Taheri T, Doroud D, Habibzadeh S, Badirzadeh A, Rafati S. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model. Parasit Immunol. 2016;38(10):599–608.
  36. Jain V, Gupta A, Pawar VK, Asthana S, Jaiswal AK, Dube A, Chourasia MK. Chitosan-assisted immunotherapy for intervention of experimental Leishmaniasis via amphotericin B-loaded solid lipid nanoparticles. Appl Biochem Biotechnol. 2014;174(4):1309–30.
  37. Omwoyo WN, Melariri P, Gathirwa JW, Oloo F, Mahanga GM, Kalombo L, Ogutu B, Swai H. Development, characterization and antimalarial efficacy of dihydroartemisinin loaded solid lipid nanoparticles. Nanomed Nanotechnol Biol Med. 2016;12(3):801–9.
  38. Attama AA, Kenechukwu FC, Onuigbo EB, Nnamani PO, Obitte N, Finke JH, Pretor S, Müller-Goymann CC. Solid lipid nanoparticles encapsulating a fluorescent marker (coumarin 6) and antimalarials–artemether and lumefantrine: evaluation of cellular uptake and antimalarial activity. Eur J Nanomed. 2016;8(3):129–38.
  39. Dwivedi P, Khatik R, Khandelwal K, Shukla R, Paliwal SK, Dwivedi AK, Mishra PR. Preparation and characterization of solid lipid nanoparticles of antimalarial drug arteether for oral administration. J Biomater Tissue Eng. 2014;4(2):133–7.
  40. Kamarullah W, Indrajaya E, Emmanuella J. potency of luteolin with solid lipid nanoparticle (sln)-polyethylene glycol (peg) modification for artemisinin-resistant Plasmodium falciparum infection. Indonesian J Trop Infect Dis. 2018;7(3):80–6.
  41. Volpedo G, Costa L, Ryan N, Halsey G, Satoskar A, OghumuNanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases. J Venom Animal Toxin Includ Trop Dis. 2019;25: e144118. Available from: https://doi. org/10.1590/1678-9199-jvatitd-1441-18.
  42. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the Eur J Pharmaceut Biopharmaceut. 2000;50(1):161–77. Available from: https://doi.org/10.1016/s0939-6411(00)00087-4.
  43. Lu H, Zhang S, Wang J, Chen A review on polymer and lipid- based nanocarriers and its application to nano-pharmaceutical and food-based systems. Front Nutr. 2021; 8:783831. Available from: https://doi.org/10.3389/fnut.2021.783831.
  44. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/ biocompatible polymer-based nanocarriers for drug Chem Soc Rev. 2013;42(3):1147–Available from: https://doi.org/10.1039/c2cs35265f.
  45. Guimarães D, Cavaco-Paulo A, Nogueira Design of liposomes as drug delivery system for therapeutic applications. Int J Pharmaceut. 2021;601:120571. Available from: https://doi. org/10.1016/j.ijpharm.2021.120571.
  46. Allen TM, Cullis Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. Available from: https://doi.org/10.1016/j. addr.2012.09.037.
  47. Jacob S, Nair AB, Shah J, Gupta S, Boddu SHS, Sreeharsha N, Joseph A, Shinu P, Morsy Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy-an overview on recent advances. Pharmaceutics. 2022. Available from: https:// doi.org/10.3390/pharmaceutics14030533.
  48. Dhiman N, Awasthi R, Sharma B, Kharkwal H, Kulkarni GT. Lipid nanoparticles as carriers for bioactive delivery. Front Chem. 2021; 9:580118. Available from: https://doi.org/10.3389/ 2021.580118.
  49. Uner M, Yener Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed. 2007;2(3):289–300.
  50. Satapathy S, Patro Solid lipid nanoparticles for efficient oral delivery of tyrosine kinase inhibitors: a nano-targeted cancer drug delivery. Adv Pharmaceut Bull. 2022;12(2):298–308. Available from: https://doi.org/10.34172/apb.2022.041.
  51. Mishra V, Bansal KK, Verma A, Yadav N, Thakur S, Sudhakar K, Rosenholm Solid lipid nanoparticles: emerging colloidal nano drug delivery systems. Pharmaceutics. 2018. Available from: https://doi.org/10.3390/pharmaceutics10040191.
  52. Pink DL, Loruthai O, Ziolek RM, Wasutrasawat P, Terry AE, Lawrence MJ, Lorenz CD. On the structure of solid lipid nanoparticles. Small. 2019;15(45): e1903156. Available from: https://doi.org/10.1002/smll.201903156.
  53. Ghasemiyeh P, Mohammadi-Samani Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems:applications, advantages and disadvantages. Res Pharmaceut Sci. 2018;13(4):288–303. Available from: https://doi.org/10.4103/1735- 5362.235156.
  54. Kaur R, Singh J, Avti PK, Kumar V, Kumar Anisotropic Gold Nanoparticles Synthesized using Litchi chinensis Leaf Extract and their Effect on Breast Cancer. International Journal of Drug Delivery Technology. 2023;13(4):1131-1138.
  55. Sharma D, Sharma A, Ghosh N, Singh R, Singh P, Mishra DK. Application of Box-Behnken Design in Optimization of Clobetasol-loaded Nanostructured Lipid Carrier for Topical Use. International Journal of Drug Delivery Technology. 2023;13(4):1186-1193.
  56. Inglut CT, Sorrin AJ, Kuruppu T, Vig S, Cicalo J, Ahmad H, Huang Immunological and toxicological considerations for the design of liposomes. Nanomaterials (Basel, Switzerland). 2020. Available from: https://doi.org/10.3390/nano10020190.
  57. Wong HL, Bendayan R, Rauth AM, Li Y, Wu Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):491–504. Available from: https:// doi.org/10.1016/j.addr.2007.04.008.
  58. Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomed. 2017; 12:7291–309. Available from: https://doi.org/10.2147/ijn.s146315.
  59. Lingayat VJ, Zarekar NS, Shendge Solid lipid nanoparticles: a review. Nanosci Nanotech Res. 2017;4(2):67–72.
  60. Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, Yang CH. Solid lipid nanoparticles (slns): an advanced drug delivery system targeting brain through Pharmaceutics. 2021. Available from: https://doi.org/10.3390/pharmaceutics13081183.
  61. Manjunath K, Venkateswarlu V. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control 2005;107(2):215–28. Available from: https://doi. org/10.1016/j.jconrel.2005.06.006.
  62. Martins SM, Sarmento B, Nunes C, Lúcio M, Reis S, Ferreira DC. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharmaceut Biopharmaceut. 2013;85(3):488–502. Available from: https://doi.org/10.1016/j.ejpb.2013.08.011.
  63. Wang X, Chen H, Luo Z, Fu X. Preparation of starch nanoparticles in water in oil microemulsion system and their drug delivery Carbohydr Polym. 2016; 138:192–200. Available from: https://doi.org/10.1016/j.carbpol.2015.11.006.
  64. Zur Mühlen A, Schwarz C, Mehnert Solid lipid nanoparticles (SLN) for controlled drug delivery–drug release and release mechanism. Eur J Pharmaceut Biopharmaceut. 1998;45(2):149–Available from: https://doi.org/10.1016/s0939-6411(97)00150- 1.
  65. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–96. Available from: https://doi.org/10.1016/ s0169-409x(01)00105-3.
  66. Dikmen G, Guney G, Genc L. Characterization of solid lipid nanoparticles containing caffeic acid and determination of its effects on MCF-7 Recent Patents Anti-Cancer Drug Discov. 2015;10(2):224–32. Available from: https://doi.org/10.2174/1574 892810666150115124413.
  67. Guillot A, Couffin AC, Sejean X, Navarro F, Limberger M, Lehr CM. Solid phase extraction as an innovative separation methodfor measuring free and entrapped drug in lipid nanoparticles. Pharmaceut Res. 2015;32(12):3999–4009. Available from: https:// doi.org/10.1007/s11095-015-1761-8.
  68. Venishetty VK, Parikh N, Sistla R, Ahmed FJ, Diwan PV. Application of validated RP-HPLC method for simultaneous determination of docetaxel and ketoconazole in solid lipid nanoparticles. J Chromatogr Sci. 2011;49(2):136–41. Available from: https://doi.org/10.1093/chrsci/49.2.136.
  69. Lv Y, He H, Qi J, Lu Y, Zhao W, Dong X, Wu W. Visual validation of the measurement of entrapment efficiency of drug nanocarriers. Int J 2018;547(1):395–403. Available from: https://doi.org/10.1016/j.ijpharm.2018.06.025.
  70. Berry MR, Likar MD. Statistical assessment of dissolution and drug release profile similarity using a model-dependent J Pharmaceut Biomed Anal. 2007;45(2):194–200. Available from: https://doi.org/10.1016/j.jpba.2007.05.021.
  71. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Laylof T, Viswanathan CT, Cook CE, McDowall Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet. 1991;16(4):249–55. Available from: https://doi.org/10.1007/bf03189968.
  72. Arvaniti EC, Juenger MCG, Bernal SA, Duchesne J, Courard L, Leroy S, Provis JL, Klemm A, De Belie N. Determination of particle size, surface area, and shape of supplementary cementitious materials by different techniques. Mater Struct. 2015;48(11):3687–701. Available from: https://doi.org/10.1617/ s11527-014-0431-3.
  73. Kakkar D, Dumoga S, Kumar R, Chuttani K, Mishra AK. PEGylated solid lipid nanoparticles: design, methotrexate loading and biological evaluation in animal Med Chem Commun. 2015;6(8):1452–63. Available from: https://doi.org/10.1039/ C5MD00104H.
  74. Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, Mozafari Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018. Available from: https://doi.org/10.3390/pharmaceutics10020057.
  75. Xu Progress in nanoparticles characterization: sizing and zeta potential measurement. Particuology. 2008;6(2):112–5. Available from: https://doi.org10.1016/j.partic.2007.12.002.
  76. Pang LSK, Saxby JD, Chatfeld SP. Thermogravimetric analysis of carbon nanotubes and nanoparticles. J Phys Chem. 1993;97(27):6941–2. Available from: https://doi.org/10.1021/
  77. Melo MN, Pereira FM, Rocha MA, Ribeiro JG, Junges A, Monteiro WF, Diz FM, Ligabue RA, Morrone FB, Severino P, Fricks Chitosan and chitosan/PEG nanoparticles loaded with indole-3-carbinol: characterization, computational study and potential effect on human bladder cancer cells. Mater Sci Eng2021; 124:112089. Available from: https://doi.org/10.1016/j. msec.2021.112089.
  78. Esposito E, Sguizzato M, Drechsler M, Mariani P, Carducci F, Nastruzzi C, Cortesi Progesterone lipid nanoparticles: Scaling up and in vivo human study. Eur J Pharmaceut Biopharmaceut. 2017; 119:437–46. Available from: https://doi.org/10.1016/j. ejpb.2017.07.015.
  79. Ravani L, Esposito E, Bories C, Moal VL, Loiseau PM, Djabourov M, Cortesi R, Bouchemal K. Clotrimazole-loaded nanostructured lipid carrier hydrogels: thermal analysis and in vitro studies. Int J Pharmaceut. 2013;454(2):695–702. Available from: https://doi.org/10.1016/j.ijpharm.2013.06.015.
  80. Patil H, Kulkarni V, Majumdar S, Repka MA. Continuous manufacturing of solid lipid nanoparticles by hot melt Int J Pharmaceut. 2014;471(1):153–6. Available from: https://doi. org/10.1016/j.ijpharm.2014.05.024.
  81. Carbone C, Tomasello B, Ruozi B, Renis M, Puglisi G. Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial Eur J Med Chem. 2012;49:110–7. Available from: https://doi.org/10.1016/j.ejmech.2012.01.001.
  82. Nabi-Meibodi M, Vatanara A, Najafabadi AR, Rouini MR, Ramezani V, Gilani K, Etemadzadeh SMH, Azadmanesh K. The effective encapsulation of a hydrophobic lipid-insoluble drug in solid lipid nanoparticles using a modified double emulsion solvent evaporation method. Colloid Surface B Biointerfaces. 2013;112:408–14. Available from: https://doi.org/10.1016/j. colsurf 2013.06.013.
  83. Kotmakçı M, Akbaba H, Erel G, Ertan G, Kantarcı Improved method for solid lipid nanoparticle preparation based on hot microemulsions: preparation, characterization, cytotoxicity, and hemocompatibility evaluation. AAPS Pharm Sci Tech. 2017;18(4):1355–65. Available from: https://doi.org/10.1208/ s12249-016-0606-z.
  84. Battaglia L, Gallarate M, Cavalli R, Trotta M. Solid lipid nanoparticles produced through a coacervation method. J Microencapsul. 2010;27(1):78–85. Available from: https://doi. org/10.3109/02652040903031279.
  85. Charcosset C, El-Harati A, Fessi H. Preparation of solid lipid nanoparticles using a membrane contactor. J Control Releas. 2005;108(1):112–20. Available from: https://doi.org/10.1016/j. 2005.07.023.
  86. Passerini N, Gavini E, Albertini B, Rassu G, Di Sabatino M, Sanna V, Giunchedi P, Rodriguez Evaluation of solid lipid microparticles produced by spray congealing for topical application of econazole nitrate. J Pharm Pharmacol. 2009;61(5):559–67. Available from: https://doi.org/10.1211/ jpp.61.05.0003.
  87. Souto EB, Doktorovova S, Zielinska A, Silva AM. Key production parameters for the development of solid lipid nanoparticles by high shear homogenization. Pharmaceut Develop Technol. 2019;24(9):1181–5. Available from: https://doi.org/10.1080/108 2019.1647235.
  88. Nair AB, Shah J, Al-Dhubiab BE, Jacob S, Patel SS, Venugopala KN, Morsy MA, Gupta S, Attimarad M, Sreeharsha N, Shinu P. Clarithromycin solid lipid nanoparticles for topical ocular therapy: optimization, evaluation and in vivo studies. Pharmaceutics. 2021. Available from: https://doi.org/10.3390/
  89. Pooja D, Tunki L, Kulhari H, Reddy BB, Sistla Optimization of solid lipid nanoparticles prepared by a single emulsification- solvent evaporation method. Data Brief. 2016;6:15–9. Available from: https://doi.org/10.1016/j.dib.2015.11.038.
  90. Maleki G, Bahrami Z, Woltering EJ, Khorasani S, Mozafari MR. A review of patents on “Mozafari Method” as a green technology for manufacturing bioactive carriers. Biointerface Res Appl Chem. 2023;13:1.
  91. Nasrollahzadeh M, Sajjadi M, Sajadi SM, Issaabadi Z. Chapter 5-Green nanotechnology. In: Nasrollahzadeh M, Sajadi SM, Sajjadi M, Issaabadi Z, Atarod M, editors. An introduction to green nanotechnology, vol. 28. Elsevier; 2019. p. 145–98.
  92. Kumar A. Improving secondary metabolite production in tissue cultures. Plant Biol Biotechnol. 2015;8:397–406.
  93. Mozafari MR, Javanmard R, Raji M. Tocosome: novel drug delivery system containing phospholipids and tocopheryl phosphates. Int Pharmaceut. 2017;528(1–2):381–2. Available from: https://doi.org/10.1016/j.ijpharm.2017.06.037.
  94. Mozafari MR. Nanoliposomes: preparation and analysis. Method Mol Biol (Clifton, NJ). 2010;605:29–50. Available from: https:// org/10.1007/978-1-60327-360-2_2.
  95. Mohammadi L, Pal K, Bilal M, Rahdar A, Fytianos G, Kyzas GZ. Green nanoparticles to treat patients with Malaria disease: an overview. JMolr Struct. 2021;1229:129857.
  96. Rahman K, Khan SU, Fahad S, Chang MX, Abbas A, Khan WU, Rahman L, Haq ZU, Nabi G, Khan Nanobiotechnology: a new approach to treat and prevent malaria. Int J Nanomed. 2019;14:1401–10. Available from: https://doi.org/10.2147/ijn. s190692.
  97. Radwan A, El-Lakkany N, William S, El-Feky G, Al-Shorbagy M, Saleh S, Botros A novel praziquantel solid lipid nanoparticle formulation shows enhanced bioavailability and antischistosomal efficacy against murine S. mansoni infection. Parasite Vectors. 2019. Available from: https://doi.org/10.1186/s13071-019-3563-z.
  98. de Souza AL, Andreani T, de Oliveira RN, Kiill CP, dos Santos FK, Allegretti SM, Chaud MV, Souto EB, Silva AM, Gremião MP. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis Int J Pharm. 2014;463(1):31–7. Available from: https:// doi.org/10.1016/j.ijpharm.2013.12.022.
  99. Rafei A, Soltani S, Ramezani Z, Abbaspour MR, Jelowdar A, Kahvaz Ultrastructural changes on fertile and infertile hydatid cysts induced by conventional and solid lipid nanoparticles of albendazole and albendazole sulfoxide. Compr Clin Pathol. 2019;28(4):1045–53.
  100. Soltani S, Rafei A, Ramezani Z, Abbaspour MR, Jelowdar A, Kahvaz MS. Evaluation of the hydatid cyst membrane permeability of albendazole and albendazole sulfoxide-loaded solid lipid nanoparticles. Jundishapur J Natural Pharmaceut Product. 2017;12:2.
  101. Andrade LN, Marques C, Barbosa T, Santos R, Chaud MV, da Silva CF, Corrêa CB, Amaral RG, de Souza NR, Gonsalves JKM. Praziquantel-loaded solid lipid nanoparticles: production, physicochemical characterization, release profile, cytotoxicity and in vitro activity against Schistosoma J Drug Deliv Sci Technol. 2020;58:101784.
  102. Xie S, Pan B, Shi B, Zhang Z, Zhang X, Wang M, Zhou Solid lipid nanoparticle suspension enhanced the therapeutic efficacy of praziquantel against tapeworm. Int J Nanomed. 2011;6:2367.
  103. Sharma S, Goel V, Kaur P, Gadhave K, Garg N, Singla LD, Choudhury D. Bioinspired dual-functional solid lipid nanoformulations for targeted drug delivery and sustained release for enhancement of potency of albendazole, an antihelminthic bioRxiv. 2021. Available from: https://doi. org/10.1101/2021.07.24.453620.
  104. Ahmadnia S, Moazeni M, Mohammadi-Samani S, Oryan A. In vivo evaluation of the efficacy of albendazole sulfoxide and albendazole sulfoxide loaded solid lipid nanoparticles against hydatid cyst. Exp Parasitol. 2013;135(2):314–9.
  105. Kudtarkar A, Shinde U, Bharkad G, Singh Solid lipid nanoparticles of albendazole for treatment of Toxocara canis infection: in-vivo efficacy studies. Nanosci Nanotechnol Asia. 2017;7(1):80–91.
  106. Petrovska BB. Historical review of medicinal plants’ usage. Pharmacog Rev. 2012;6(11):1–5. Available from: https://doi. org/10.4103/0973-7847.95849.
  107. Tucakov Healing with plants–phytotherapy. Beograd Cult. 1971;8:180–90.
  108. Mohammad Rahimi H, Khosravi M, Hesari Z, Sharifdini M, Mirjalali H, Zali MR. Anti-toxoplasma activity and chemical compositions of aquatic extract of Mentha pulegium and Rubus idaeus L.: an in vitro study. Food Sci Nutr. 2020;8(7):3656–64. Available from: https://doi.org/10.1002/fsn3.1648.
  109. Obeid MA, Al Qaraghuli MM, Alsaadi M, Alzahrani AR, Niwasabutra K, Ferro VA. Delivering natural products and biotherapeutics to improve drug efficacy. Therapeut Deliv. 2017;8(11):947–56. Available from: https://doi.org/10.4155/tde- 2017-0060.
  110. Lam PL, Wong WY, Bian Z, Chui CH, Gambari R. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern. Nanomedicine (Lond). 2017;12(4):357–85. Available from: https://doi.org/10.2217/nnm- 2016-0305.
  111. Jafarpour Azami S, Mohammad Rahimi H, Mirjalali H, Zali Unravelling Toxoplasma treatment: conventional drugs toward nanomedicine. World J Microbiol Biotechnol. 2021;37(3):48. Available from: https://doi.org/10.1007/s11274-021-03000-x.
  112. Yadav D, Suri S, Choudhary AA, Sikender M, Hemant BN, Beg NM. Novel approach: Herbal remedies and natural products in pharmaceutical science as nano drug delivery systems. Int J Pharm Tech. 2011;3(3):3092–116.
  113. Singh RP, Singh SG, Naik H, Jain D, Bisla S. Herbal excipients in novel drug delivery system. Int J Compr Pharm. 2011;2:1–7. 114.G unasekaran T, Haile T, Nigusse T, Dhanaraju MD.
  114. Nanotechnology: an effective tool for enhancing bioavailability and bioactivity of phytomedicine. Asian Pacific J Trop Biomed. 2014;4:S1–7. Available from: https://doi.org/10.12980/ APJTB.4.2014C980.
  115. Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomed Nanotechnol Biol Med. 2010;6(6):753–9.
  116. Sutthanut K, Lu X, Jay M, Sripanidkulchai B. Solid lipid nanoparticles for topical administration of Kaempferia parviflora extracts. J Biomed Nanotechnol. 2009;5(2):224–32. Available from: https://doi.org/10.1166/jbn.2009.1026.
  117. Dasam JM, Natarajan J, Karri V, Wadhwani AD, Antony Targeting efficacy of simvastatin for hormone-dependent carcinomas through solid lipid nanoparticles. J Nanomed Nanotechnol. 2016;7(6):1–7.
  118. Shewale PB, Patil RA, Hiray YA. Antidepressant-like activity of anthocyanidins from Hibiscus rosa-sinensis flowers in tail suspension test and forced swim test. Indian J Pharmacol. 2012;44(4):454.
  119. Vijayanand P, Jyothi V, Aditya N, Mounika A. Development and characterization of solid lipid nanoparticles containing herbal extract: in vivo antidepressant J Drug Deliv. 2018;2018:2908626. Available from: https://doi. org/10.1155/2018/2908626.
  120. Campos DA, Madureira AR, Sarmento B, Gomes AM, Pintado Stability of bioactive solid lipid nanoparticles loaded with herbal extracts when exposed to simulated gastrointestinal tract conditions. Food Res Int. 2015;78:131–40. Available from: https:// doi.org/10.1016/j.foodres.2015.10.025.
  121. Rajwar TK, Pradhan D, Halder J, Rai VK, Kar B, Ghosh G, Rath G. Opportunity in nanomedicine to counter the challenges of current drug delivery approaches used for the treatment of malaria: a J Drug Target. 2023;31(4):354–68. Available from: https://doi.org/10.1080/1061186x.2022.2164290.
  122. Mutabingwa TK. Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! Act 2005;95(3):305–15. Available from: https://doi. org/10.1016/j.actatropica.2005.06.009.
  123. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7(12):864–74. Available from: https://doi. org/10.1038/nrmicro2239.
  124. Baden L, Catteruccia F, Diabaté A, Donini C, Nosten F, O’Neill S, Osier F, Phyo AP, White Malaria-epidemiology, treatment, and prevention. New Engl J Med. 2023;388(5):e9. Available from: https://doi.org/10.1056/NEJMp2216703.
  125. Yasri S, Wiwanitkit V. Artemisinin resistance: an important emerging clinical problem in tropical medicine. Int J Physiol Pathophysiol Pharmacol. 2021;13(6):152–7.
  126. Ye R, Hu D, Zhang Y, Huang Y, Sun X, Wang J, Chen X, Zhou H, Zhang D, Mungthin M, Pan W. Distinctive origin of artemisinin-resistant Plasmodium falciparum on the China- Myanmar Sci Rep. 2016;6:20100. Available from: https:// doi.org/10.1038/srep20100.
  127. Fola AA, Feleke SM, Mohammed H, Brhane BG, Hennelly CM, Assefa A, Crudal RM, Reichert E, Juliano JJ, Cunningham J, Mamo H, Solomon H, Tasew G, Petros B, Parr JB, Bailey JA. Plasmodium falciparum resistant to artemisinin and diagnostics have emerged in Ethiopia. Nat Microbiol. 2023;8(10):1911–9. Available from: https://doi.org/10.1038/s41564-023-01461-4.
  128. Greenwood B. Artemisinin-resistant and hrp-negative malaria parasites in Africa. New Engl J Med. 2023;389(13):1162–4. Available from: https://doi.org/10.1056/NEJMp2309142.
  129. Miean KH, Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agricult Food Chem. 2001;49(6):3106–12. Available from: https://doi.org/10.1021/jf000892m.
  130. Tasdemir D, Lack G, Brun R, Rüedi P, Scapozza L, Perozzo Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation,of fabg, fabz, and fabi as drug targets for flavonoids. J Med Chem. 2006;49(11):3345–53. https://doi.org/10.1021/ jm0600545.
  131. Lehane AM, Saliba Common dietary flavonoids inhibit the growth of the intraerythrocytic malaria parasite. BMC Res Notes. 2008;1(1):26. Available from: https://doi.org/10.1186/1756- 0500-1-26.
  132. Goy RC, Britto Dd, Assis A review of the antimicrobial activity of chitosan. Polímeros. 2009;19:241–7.
  133. No HK, Park NY, Lee SH, Meyers Antibacterial activity of chitosans and chitosan oligomers with different molecular weights. Int J Food Microbiol. 2002;74(1–2):65–72. Available from: https://doi.org/10.1016/s0168-1605(01)00717-6.
  134. Stan D, Enciu A-M, Mateescu AL, Ion AC, Brezeanu AC, Stan D, Tanase C. Natural compounds with antimicrobial and antiviral effect and nanocarriers used for their transportation. Front Pharmacol. 2021;12:25.
  135. Mikušová V, Mikuš P. Advances in chitosan-based nanoparticles for drug Int J Mol Sci. 2021. Available from: https://doi. org/10.3390/ijms22179652.
  136. Shin GH, Kim JT. Observation of chitosan coated lipid nanoparticles with different lipid compositions under simulated in vitro digestion system. Food Hydrocolloid. 2018;84:146–53. Available from: https://doi.org/10.1016/j.foodhyd.2018.05.052.
  137. Wang J-y, Wang Y, Meng X. Chitosan nanolayered cisplatin- loaded lipid nanoparticles for enhanced anticancer efficacy in cervical cancer. Nanoscale Res Lett. 2016;11(1):524. Available from: https://doi.org/10.1186/s11671-016-1698-9.
  138. Liu H, Li Y, Zhang X, Shi M, Li D, Wang Chitosan-coated solid lipid nano-encapsulation improves the therapeutic anti- airway inflammation effect of berberine against COPD in cigarette smoke-exposed rats. Can Respir J. 2022;2022:8509396. Available from: https://doi.org/10.1155/2022/8509396.
  139. Kong M, Chen XG, Xing K, Park HJ. Antimicrobial properties of chitosan and mode of action: a state of the art review. Int J Food Microbiol. 2010;144(1):51–63. Available from: https://doi. org/10.1016/j.ijfoodmicro.2010.09.012.
  140. Teimouri A, Azami SJ, Keshavarz H, Esmaeili F, Alimi R, Mavi SA, Shojaee S. Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain. Int J Nanomed. 2018;13:1341–51. Available from: https://doi.org/10.2147/ijn.
  141. Teimouri A, Haghi AM, Nateghpour M, Farivar L, Hanifian H, Mavi SA, Zare Antimalarial efficacy of low molecular weight chitosan against Plasmodium berghei infection in mice. J Vector Borne Dis. 2016;53(4):312–6.
  142. Tavassoli M, Imani A, Tajik H, Moradi M, Pourseyed Novel in vitro efficiency of chitosan biomolecule against Trichomonas gallinae. Iran J Parasitol. 2012;7(1):92–6.
  143. Yarahmadi M, Fakhar M, Ebrahimzadeh MA, Chabra A, Rahimi-Esboei B. The anti-giardial effectiveness of fungal and commercial chitosan against Giardia intestinalis cysts in vitro. J Parasit Dis. 2016;40(1):75–80. Available from: https://doi. org/10.1007/s12639-014-0449-z.
  144. Parvez S, Yadagiri G, Karole A, Singh OP, Verma A, Sundar S, Mudavath SL. Recuperating biopharmaceutical aspects of amphotericin B and paromomycin using a chitosan functionalized nanocarrier via oral route for enhanced anti-Leishmanial activity. Front Cell Infect Microbiol. 2020;10:24.
  145. Riezk A, Van Bocxlaer K, Yardley V, Murdan S, Croft SL. Activity of amphotericin B-loaded chitosan nanoparticles against experimental cutaneous Leishmania Molecules. 2020. Available from: https://doi.org/10.3390/molecules25174002.
  146. Haddad A, Delavari M, Arbabi M, Gardeshmeydani I, Salmani Evaluation of anti-Leishmaniasis activity of curcumin-loaded chitosan nanoparticles on Leishmania major and L. infantum in vitro. FEYZ. 2021;25(4):1040–6.
  147. Riezk A, Raynes JG, Yardley V, Murdan S, Croft SL. Activity of Chitosan and its derivatives against Leishmania major and Leishmania mexicana in vitro. Antimicrob Agents Chemother. 2020. Available from: https://doi.org/10.1128/aac.01772-19.
  148. Hassan MM, Abd El-Rahman EM, Abd El-Hamed EF, Abdel Fattah AS, Harb OA, Mohamed SAEN, Sarhan The impact of nitazoxanide-loaded on solid lipid nanoparticles on experimental trichinellosis. Zagazig Univ Med J. 2021;27(6):1074 –84. Available from: https://doi.org/10.21608/zumj.2019.16531.1480.
  149. Singh A, Mishra A, Chaudhary R, Kumar Role of herbal plants in prevention and treatment of parasitic diseases. J Sci Res. 2020;64:50–8.
  150. Capela R, Moreira R, Lopes An overview of drug resistance in protozoal diseases. Int J Mol Sci. 2019. Available from: https:// doi.org/10.3390/ijms20225748.
  151. Monzote L, Siddiq Drug development to protozoan diseases. Open Med Chem J. 2011;5:1–3. Available from: https://doi.org/1 0.2174/1874104501105010001.
  152. Kalepu S, Manthina M, Padavala V. Oral lipid-based drug delivery systems—an overview. Acta Pharmaceut Sin B. 2013;3(6):361–72. Available from: https://doi.org/10.1016/j. 2013.10.001.
  153. Nakmode D, Bhavana V, Thakor P, Madan J, Singh PK, Singh SB, Rosenholm JM, Bansal KK, Mehra NK. Fundamental aspects of lipid-based excipients in lipid-based product development. Pharmaceutics. 2022. Available from: https://doi.org/10.3390/
  154. Wiesgigl M, Clos Heat shock protein 90 homeostasis controls stage differentiation in Leishmania donovani. Mol Biol Cell. 2001;12(11):3307–16. Available from: https://doi.org/10.1091/ mbc.12.11.3307.
  155. Petersen A, Campos TA, Dantas D, Rebouças JS, da Silva JC, de Menezes JPB, Formiga FR, de Melo JV, Machado G, Veras PST. Encapsulation of the HSP-90 chaperone inhibitor 17-AAG in stable liposomes allow increasing the therapeutic index as assessed, in vitro, on Leishmania (L) amazonensis amastigotes-hosted in mouse cba Front Cell Infect Microbiol. 2018;8:303. Available from: https://doi.org/10.3389/ fcimb.2018.00303.
  156. Neva FA, Brown HW. Basic clinical parasitology; 1994. 157.Sepulveda MS, Kinsella Helminth collection and identification from wildlife. J Vis Exp. 2013;82:e51000. Available from: https://doi.org/10.3791/51000.
  157. Martin RJ. Modes of action of anthelmintic drugs. Vet J. 1997;154(1):11–34. Available from: https://doi.org/10.1016/S1090- 0233(05)80005-X.
  158. Lloyd AE, Honey BL, John BM, Condren Treatment options and considerations for intestinal helminthic infections. J Pharm Technol. 2014;30(4):130–9. Available from: https://doi. org/10.1177/8755122514533667.
  159. Giordani C, Marin G, Pérez D, Soraci A, Errecalde J. Mechanism of action of drugs with activity against multicellular parasites. Parazitologiya. 2017;51:294–316.
  160. Fissiha W, Kinde Anthelmintic resistance and its mechanism: a review. Infect Drug Resist. 2021;14:5403–10. Available from: https://doi.org/10.2147/idr.s332378.
  161. McCracken RO, Taylor Biochemical effects of thiabendazole and cambendazole on Hymenolepis diminuta (cestoda) in vivo. J Parasitol. 1983;69(2):295–301. Available from: https://doi. org/10.2307/3281226.
  162. Pham K, Mertelsmann A, Mages K, Kingery JR, Mazigo HD, Jaka H, Kalokola F, Changalucha JM, Kapiga S, Peck RN, Downs JA. Effects of helminths and anthelmintic treatment on cardiometabolic diseases and risk factors: a systematic review. PLOS Negl Trop Dis. 2023;17(2):e0011022. Available from: https://doi.org/10.1371/journal.pntd.0011022.
  163. Frayha GJ, Smyth JD, Gobert JG, Savel J. The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen Pharmacol Vascul Syst. 1997;28(2):273–99. Available from: https://doi.org/10.1016/S0306-3623(96)00149-8.
  164. Chen W, Mook RA Jr, Premont RT, Wang J. Niclosamide: beyond an antihelminthic drug. Cell Signal. 2018;41:89–96. Available from: https://doi.org/10.1016/j.cellsig.2017.04.001.
  165. Castro-Hermida JA, González-Warleta M, Martínez-Sernández V, Ubeira FM, Mezo M. Current challenges for fasciolicide treatment in ruminant Trend Parasitol. 2021;37(5):430–Available from: https://doi.org/10.1016/j.pt.2020.12.003. 167.Mukherjee N, Mukherjee S, Saini DP, Roy P, Babu S. Phenolics
  166. and terpenoids; the promising new search for anthelmintics: a critical review. Mini Rev Med Chem. 2015. Available from: https://doi.org/10.2174/1389557515666150227114824.
  167. Charvet CL, Guégnard F, Courtot E, Cortet J, Neveu Nicotine- sensitive acetylcholine receptors are relevant pharmacological targets for the control of multidrug resistant parasitic nematodes. Int J Parasitol Drugs Drug Resist. 2018;8(3):540–9. Available from: https://doi.org/10.1016/j.ijpddr.2018.11.003.
  168. Page SW. Chapter 10-Antiparasitic drugs. In: Maddison JE, Page SW, Church DB, editors. Small animal clinical pharmacology. 2nd Edinburgh: W.B. Saunders; 2008. p. 198–260. Available from: https://doi.org/10.1016/B978-070202858-8.50012-9.
  169. Holden-Dye L, Walker Anthelmintic drugs and nematicides: studies in Caenorhabditis elegans. London: WormBook; 2014. p. 1–29. Available from: https://doi.org/10.1895/wormbook.1.143.2.
  170. Beech RN, Skuce P, Bartley DJ, Martin RJ, Prichard RK, Gilleard JS. Anthelmintic resistance: markers for resistance, or susceptibility? Parasitology. 2011;138(2):160–74. Available from: https://doi.org/10.1017/s0031182010001198.
  171. Thomas CM, Timson DJ. The mechanism of action of praziquantel: can new drugs exploit similar mechanisms? Curr Med 2020;27(5):676–96. Available from: https://doi.org/ 10.2174/0929867325666180926145537.
  172. Eissa MM, El-Azzouni MZ, El-Khordagui LK, Abdel Bary A, El-Moslemany RM, Abdel Salam SA. Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni. Parasite Vectors. 2020;13:1–12.
  173. G nanasekar M, Salunk he AM, Mallia AK, He YX, Kalyanasundaram R. Praziquantel affects the regulatory myosin light chain of Schistosoma Antimicrob Agents Chemother. 2009;53(3):1054–60. Available from: https://doi. org/10.1128/aac.01222-08.
  174. Kabatende J, Barry A, Mugisha M, Ntirenganya L, Bergman U, Bienvenu E, Aklillu E. Safety of praziquantel and albendazole coadministration for the control and elimination of schistosomiasis and soil-transmitted helminths among children in Rwanda: an active surveillance study. Drug Saf. 2022;45(8):909–22. Available from: https://doi.org/10.1007/s40264-022-01201-3.
  175. Lifschitz A, Lanusse C, Alvarez L. Host pharmacokinetics and drug accumulation of anthelmintics within target helminth parasites of N Z Vet J. 2017;65(4):176–84. Available from: https://doi.org/10.1080/00480169.2017.1317222.
  176. Eskandari M, Asgharzadeh F, Askarnia-faal MM, Naimi H, Avan A, Ahadi M, Vossoughinia H, Gharib M, Soleimani A, Naghibzadeh N, Ferns G, Ryzhikov M, Khazaei M,
  177. Hassanian SM. Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis. Sci Rep. 2022;12(1):10249. Available from: https://doi.org/10.1038/s41598-022-14420-6.
  178. Li P, Rios Coronado PE, Longstaff XRR, Tarashansky AJ, Wang Nanomedicine approaches against parasitic worm infections. Adv Healthc Mater. 2018;7(13):e1701494. Available from: https:// doi.org/10.1002/adhm.201701494.
  179. Paredes AJ, Llabot JM, Sanchez Bruni S, Allemandi D, Palma SD. Self-dispersible nanocrystals of albendazole produced by high pressure homogenization and spray-drying. Drug Develop Industr Pharm. 2016;42(10):1564–70.
  180. Fontana F, Figueiredo P, Zhang P, Hirvonen JT, Liu D, Santos HA. Production of pure drug nanocrystals and nano co-crystals by confinement Adv Drug Deliv Rev. 2018;131:3–21.
  181. Barbosa EJ, Löbenberg R, de Araujo GLB, Bou-Chacra NA. Niclosamide repositioning for treating cancer: challenges and nano-based drug delivery opportunities. Eur J Pharmaceut Biopharmaceut. 2019;141:58–69.
  182. Abidi H, Ghaedi M, Rafei A, Jelowdar A, Salimi A, Asfaram A, Ostovan A. Magnetic solid lipid nanoparticles co-loaded with albendazole as an antiparasitic drug: sonochemical preparation, characterization, and in vitro drug release. J Mol Liq. 2018;268:11–8.
  183. Mishra A, Vuddanda PR, Singh Intestinal lymphatic delivery of praziquantel by solid lipid nanoparticles: formulation design, in vitro and in vivo studies. J Nanotechnol. 2014;2014:8.
  184. Xiang B, Cao D-Y. Preparation of drug liposomes by thin-film hydration and homogenization. In: Lu W-L, Qi X-R, editors. Liposome-based drug delivery Berlin: Springer; 2017.1–11.
  185. Skuhala T, Trkulja V, Runje M, Vukelic D, Desnica B. Albendazole sulphoxide concentrations in plasma and hydatid cyst and prediction of parasitological and clinical outcomes in patients with liver hydatidosis caused by Echinococcus Croatian Med J. 2014;55(2):146–55. Available from: https://doi.org/10.3325/cmj.2014.55.146.
  186. Norbury LJ, Shirakashi S, Power C, Nowak BF, Bott NJ. Praziquantel use in aquaculture—current status and emerging issues. Int J Parasitol Drugs Drug Resist. 2022;18:87–102. Available from: https://doi.org/10.1016/j.ijpddr.2022.02.001.
  187. Coeli R, Baba EH, Araujo N, Coelho PMZ, Oliveira G. Praziquantel treatment decreases Schistosoma mansoni genetic diversity in experimental infections. PLoS Negl Trop Dis. 2013;7(12):e2596.
  188. Partridge GJ, Rao S, Woolley LD, Pilmer L, Lymbery AJ, Prestidge CA. Bioavailability and palatability of praziquantel incorporated into solid–lipid nanoparticles fed to yellowtail kingfish Seriola Compar Biochem Physiol Part C Toxicol Pharmacol. 2019;218:14–20.
  189. de Almeida AE, Souza ALR, Cassimiro DL, Gremião MPD, Ribeiro CA, Crespi Thermal characterization of solid lipid nanoparticles containing praziquantel. J Therm Analys Calorimetr. 2012;108(1):333–9.